Acetate supplementation increases brain acetyl-CoA metabolism, alters histone and non-histone protein acetylation, increases brain energy reserves, and is anti-inflammatory and neuroprotective in rat models of neuroinflammation and neuroborreliosis. To determine the impact acetate supplementation has on a mouse model of multiple sclerosis, we quantified the effect treatment had on injury progression, spinal cord lipid content, phospholipase levels, and myelin structure in mice subjected to experimental autoimmune encephalomyelitis (EAE). EAE was induced by inoculating mice with a myelin oligodendrocyte glycoprotein peptide fragment ), and acetate supplementation was maintained with 4 g/kg glyceryl triacetate by a daily oral gavage. Acetate supplementation prevented the onset of clinical signs in mice subject to EAE compared to controltreated mice. Furthermore, acetate supplementation prevented the loss of spinal cord ethanolamine and choline glycerophospholipid and phosphatidylserine in mice subjected to EAE compared to EAE animals treated with water. Treatment increased saturated and monounsaturated fatty acid levels in phosphatidylserine compared to controls suggesting that acetate was utilized to increase spinal cord fatty acid content. Also, acetate supplementation prevented the loss of spinal cord cholesterol in EAE animals but did not change cholesteryl esters. Treatment significantly increased GD3 and GD1a ganglioside levels in EAE mice when compared to EAE mice treated with water. Treatment returned levels of phosphorylated and non-phosphorylated cytosolic phospholipase A 2 (cPLA 2 ) levels back to baseline and based on FluoroMyelin TM histochemistry maintained myelin structural characteristics. Overall, these data suggest that acetate supplementation may modulate lipid metabolism in mice subjected to EAE.
A mouse model of experimental autoimmune encephalomyelitis (EAE) initiated with the inoculation of a myelin oligodendrocyte glycoprotein peptide fragment ) causes a self-antigen attack on myelin resulting in ascending paralysis. The model is used to mimic, at least in part, the autoimmune components found in multiple sclerosis lesion patterns I and II (Denic et al. 2011; Palumbo and Bosetti 2013) . The severity of paralysis in this model is a direct result of myelin loss within the spinal cord, which over time degrades both motor and neuronal function (Palumbo and Bosetti 2013) . In this regard, spinal cord white matter is composed of myelinated axons that facilitate the movement of electrical current along the axon by acting as an electrical insulator (Aggarwal et al. 2011; Chrast et al. 2011) . Myelin membranes are highly enriched in lipids that comprise approximately 70% of its content based on dry weight. Phospholipids occupy approximately 43% of the total lipid component, which includes ethanolamine glycerophospholipid (16%), choline glycerophospholipid (11%), phosphatidylserine (5%), and galactocerebroside (23%), while cholesterol occupies 28% of the total (Morell 1984) . However, total and individual spinal cord phospholipid content decreases in EAE suggesting that the loss of spinal cord lipid may precede or at least parallel loss of function (Revina et al. 2001) .
The autoimmune hypothesis, however, does not fully explain the underlying pathophysiology, genetic susceptibility, environmental and pathogen exposure, and gender specificity of that found in people who suffer from multiple sclerosis (Corthals 2011) . Multiple sclerosis is largely considered an inflammatory disease in which autoreactive T cells enter the central nervous system resulting in the loss of myelin, chronic inflammation, and neuronal damage (Zindler and Zipp 2010; Cusick et al. 2013) . As a result, current therapeutic strategies to treat people who suffer from the disease inhibit peripheral immune cell infiltration and down-regulate the inflammatory response within the central nervous system (Lim and Constantinescu 2010; Minagar 2013) . However, another factor involved in multiple sclerosis, as well as other demyelinating diseases, is the disruption of oligodendrocyte maturation and dysfunction in mature oligodendrocyte function (Lucchinetti et al. 2000; Wolswijk 2000 ; de Castro et al. 2013) . Furthermore, in multiple sclerosis there is a significant decrease in overall lipid content within the white matter tracks and a significant increase in enzyme activity of those enzymes that metabolize membrane lipid (Cumings 1969; Salvati et al. 1990) . It is also suggested that changes in energy metabolism in multiple sclerosis lesions may contribute to changes in myelin pathology (Rone et al. 2016) . Overall, the question remains whether this decrease in white matter lipid and increase in lipase activity are a direct result of the selfantigen attack and subsequent inflammatory response or because of an underlying metabolic dysfunction in lipid metabolism (Corthals 2011) . In this regard, the MOG 35-55 -induced EAE model effectively models the self-antigen attack within the spinal cord resulting in demyelination, but may also be useful to quantify the impact that alterations in lipid metabolism have on injury progression. We postulate that a metabolic dysfunction in lipid metabolism may impart contribute to myelin loss in patients who suffer from multiple sclerosis.
In addition, there are a number of demyelinating disorders associated with a dysfunction in lipid metabolism. These include, but are not limited to, Canavan disease and other peroxisomal disorders. Canavan disease results from a mutation in the gene that encodes for the enzyme aspartoacylase (EC 3.5.1.15), which releases acetate from N-acetyl aspartate (Gordon 2000; Kumar et al. 2006; Namboodiri et al. 2006) . The lack of NAA-degrading enzyme activity leads to excess accumulation of NAA in the brain and in turn a deficiency in acetate necessary for myelin lipid synthesis resulting in oligodendrocyte dysfunction, spongiform changes, and absence of myelin (Namboodiri et al. 2006) . Similarly, Zellweger syndrome and X-linked adrenoleukodystrophy, caused by a peroxisomal dysfunction in fatty acid metabolism, results in a decrease in plasmalogen content that contributes to a decrease in myelin lipid synthesis (Steinberg et al. 2004 (Steinberg et al. , 2006 Wanders and Waterham 2006) . Because a disruption in lipid metabolism can alter myelin content suggests that myelin loss in EAE may be at least in part the result of a disruption in the synthesis and/ or deposition rate of myelin lipid. Thus, a potential effective strategy to prevent or slow demyelination may involve promoting myelin lipid synthesis and/or reducing its rate of breakdown. Acetate within the central nervous system is readily converted into its CoA derivative suggesting that acetate supplementation may be a potential therapy to promote lipid synthesis. Within the central nervous system acetate and acetyl-CoA are important precursors in the synthesis of fatty acid (D'Adamo and Yatsu 1966), phospholipid (Smith 1964; Chakraborty et al. 2001) , and cholesterol (Chakraborty et al. 2001) .
Glyceryl triacetate, used to induce acetate supplementation, results in a 2.2-fold increase in brain acetyl-CoA levels and increases both protein and histone acetylation (Reisenauer et al. 2011; Soliman and Rosenberger 2011; Soliman et al. 2012b) . Furthermore, acetate supplementation in rats attenuates microglia activation, inhibits reactive astrogliosis, decreases pro-inflammatory cytokine IL-1b (Reisenauer et al. 2011; Soliman et al. 2012b) , increases anti-inflammatory cytokines, and reduces eicosanoid signaling (Soliman et al. 2012a (Soliman et al. , 2013a . Long-term treatment also increases brain phosphocreatine levels in vivo that modifies purinergic signaling by altering the expression of enzymes and receptors involved in the metabolism of adenosine suggesting a neuroprotective effect (Bhatt et al. 2013; Smith et al. 2014) . In a rat model for neuroborreliosis, acetate supplementation displays anti-inflammatory effects by decreasing microglia activation and IL-1b expression suggesting treatment may be broadly effective at altering at least two forms of inflammatory stimulus within the central nervous system (Brissette et al. 2012) . Based on the pro-inflammatory status of multiple sclerosis patients (Kawachi and Lassmann 2016 ) that can in turn stimulate cellular lipolysis pathways and alter cellular lipid homeostasis (Gonzalo et al. 2012) , suggests increasing spinal cord acetyl-CoA metabolism may influence cellular homeostasis and lipid metabolism.
Furthermore, acetate supplementation is effective in reducing tremor in a rat model for traumatic brain injury (Arun et al. 2010a ) and alters glioblastoma cell growth (Tsen et al. 2014; Long et al. 2015) further supporting its role in altering cellular metabolism. More importantly, oral glyceryl triacetate increases circulating and central nervous system levels of acetate, which reduces the need for the endogenous acetate donor N-acetyl aspartate (Mathew et al. 2005) . Subsequently, glyceryl triacetate was tested as a potential therapy for treating patients suffering from Canavan disease and shown to be safe and tolerable at high doses in tremor rats and infants with Canavan disease (Madhavarao et al. 2009; Arun et al. 2010b; Segel et al. 2011) . In addition, treatment in rat model of Canavan disease reduces the loss of myelin lipid (Arun et al. 2010b) , and in lipopolysaccharide (LPS)-stimulated BV2 microglia, acetate treatment increases fatty acid content . All of which suggests that increasing brain acetyl-CoA metabolism may alter spinal cord lipid metabolism, stimulate the rate of lipid deposition, and disrupt inflammatory signaling.
In this study, we began to test the hypothesis that increasing central nervous system acetyl-CoA metabolism will increase adult spinal cord lipid content and in turn reduce injury progression in mice subjected to EAE. To do this, we quantified the impact acetate supplementation, via a daily oral gavage of glyceryl triacetate, had on injury progression and spinal cord lipid content. We found that prophylactic treatment with glyceryl triacetate prevented the onset of clinical symptoms in these mice and attenuated the loss of many lipid components found within the spinal cord. While treatment did not fully restore all spinal cord lipid components to control levels, these results do suggest that increasing central nervous system acetyl-CoA metabolism may stimulate adult lipid deposition at a rate high enough to potentially offset that lost to EAE and reduce injury.
Methods

Materials
Reagents, reagent grade solvents, and resorcinol reagent were from EMD (Gibbstown, NJ, USA), Macron Fine Chemicals (Radnor, PA, USA), Sigma (St. Louis, MO, USA), Calbiochem (Billerica, MA, USA), and Mallinckrodt Chemicals (St. Louis, MO, USA). Thin layer chromatography plates (silica gel 60) were purchased from EMD and 1,2,3-triheptadecanoin, used as an internal standard for fatty acid analysis, was from Nu-Chek Prep (Elysian, MN, USA). Myelin oligodendroglia glycoprotein ) was purchased by AnaSpec (Fremont, CA, USA), and pertussis toxin was purchased from List Biological Laboratories (St. Campbell, CA, USA). A SuperSignal West Femto chemiluminescent substrate was purchased from Thermo (Waltham, MA USA), and materials and reagents needed for western blot analysis were purchased from BioRad (Hercules, CA, USA). Antibodies were purchased from Cell Signaling (Beverly, MA, USA), Santa Cruz (Dallas, TX, USA), or Sigma. Paraformaldehyde was purchased from Alfa Aesar (Haverhill, MA, USA), microscope slides and coverslips were purchased from VWR (Chicago, IL, USA) and Brain Research Laboratories (Waban, MA, USA), respectively. PolyFreeze was purchased from Sigma, Triton X-100 was purchased from VWR, and sucrose was purchased from EMD.
Induction of EAE and treatment
All animal procedures were performed under an approved UND animal protocol based on the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. C57BL/6 female mice (Charles River Laboratories, Portage, MI, USA), were divided into groups of four mice per cage by our animal facility personnel. After a 1-week acclimation period, the individual cages were assigned to one of four non-blinded treatment groups: EAE mice treated with water, EAE mice treated with glyceryl triacetate (GTA), control mice treated with water, and control mice treated with GTA in that order until all groups were represented. These groups were arbitrarily assigned and not randomized. In the morning of first experimental day within the animal facility, mice were treated with either water or glyceryl triacetate (4.0 g/kg body weight, once daily) by oral gavage. Ten minutes after the initial treatment, EAE was induced with a subcutaneous injection of MOG (50 lg/mouse) dissolved in complete Freund's adjuvant (Sigma). Two days after the inoculation, EAE mice received a second injection of pertussis toxin (200 ng, i.p.) (Kalyvas and David 2004) . Control mice were treated with either glyceryl triacetate or water on the first experimental day; however, these mice did not receive the subcutaneous injection of complete Freund's adjuvant or pertussis toxin. These groups of mice were included to determine whether changes in lipid content were because of treatment alone. There are limitations in using control mice instead of sham-treated mice in that the immunization procedure with adjuvant followed by pertussis toxin may introduce potential complicating effects. All mice were treated at the same time daily with an oral gavage of either water or glyceryl triacetate (4 g/kg body weight) until the end of the experimental timeframe. To insure access to food, all mice subjected to EAE were given moistened food in Petri dishes on the day the first animal demonstrated tail weakness and/or paralysis. The moistened food was replaced daily until the end of the treatment period. At the end of the treatment period, mice were anesthetized with pentobarbital (50 mg/kg, i.p.; Virbac, Fort Worth, TX, USA) and killed by cardiac perfusion using heparinized (Baxter, Deerfield, IL, USA) phosphate-buffered saline [137 mM NaCl, 2.7 mM KCl, and 10 mM phosphate (Na 2 HPO 4 /KH 2 PO 4 ) at pH 7.4]. Mice used for histochemical analysis were subsequently perfused with 4% paraformaldehyde to fix the spinal cord for myelin staining. The spinal cords used for chemical analysis were dissected out of the animals, flash frozen in liquid nitrogen, and then stored at À80°C until use. Spinal cords perfusion fixed with paraformaldehyde were stored in a 4% paraformaldehyde solution at 4°C until analysis.
Myelin staining
Before sectioning, spinal cords of control mice (n = 5), EAE mice treated with water (n = 4), and EAE mice treated with GTA (n = 5) were equilibrated overnight in 30% sucrose dissolved in phosphatebuffered saline. Twenty micrometer sections of the lumbar region of the spinal cord were made using an IEC cryostat and a myelin stain was performed using FluoroMyelin TM Green (1 : 300; Molecular Probes, Eugene, OR, USA) based on manufacturer's instructions. Images were collected using an Olympus BX50 fluorescent microscope (Olympus, Waltham, MA, USA) equipped with Spot Advanced Imaging software (Version 3.4.5, Spot Imaging Solutions, Sterling Heights, MI, USA). Values of the spinocerebellar and fasciculus length were reported as means AE SD for each group.
Behavioral testing
During the treatment period, mice were evaluated daily for signs of paralysis and assigned a clinical score. The assigned scores correspond to: 0, no symptoms; 1, flaccid tail; 2, mild hind limb weakness; 3, severe hind limb weakness; 4, hind limb paralysis; and 5, hind limb and forelimb paralysis (Kalyvas and David 2004) . All mice were acclimated to the hanging wire test on days 3-5 post-inoculation then tested at 4-5 days intervals up to day 36 to determine the impact treatment had on motor strength, balance, and grip strength. The hanging wire test involves recoding the duration (up to 60 s) that an animal is able to hold onto to a wire mesh while being inverted approximately 15 cm above a cushioned mat (Sango et al. 1996) . The sample size, described in Fig. 1 , was the total number of mice used for this analysis (n = 24). In Fig. 1 , values were reported as means AE SD for each group per testing day.
Lipid extraction
Frozen spinal cords samples of control mice (n = 6) treated with either water or GTA and EAE mice (n = 8) treated either water or GTA were weighed then extracted in a glass Tenbroeck homogenizer using n-hexane:2-propanol (3 : 2 by vol.) as described previously (Radin 1981; Bhatt and Rosenberger 2014) . The lipid extracts were collected and stored in n-hexane:2-propanol (3 : 2 by vol.) at À80°C until use.
Thin layer chromatography
Spinal cord phospholipids were isolated using thin layer chromatography (20 9 20 cm, Merck silica gel 60 plates; EMD) using a solvent system of chloroform/methanol/glacial acetic acid/water (50 : 37.5 : 3 : 2 by vol.). A second series of two-dimensional separations were performed to isolate the ethanolamine and choline plasmalogen from their parent glycerophospholipid fractions. This separation was performed on 10 9 10 cm thin layer chromatography plate using the solvent system described above in the first direction and chloroform/methanol/ammonium hydroxide (65 : 25 : 4 by vol.) system in the second direction. Between dimensions, the plates were exposed to hydrochloric acid fumes to hydrolyze the vinyl ether linkage found in the plasmalogen fractions. Bands corresponding to 1-O-alkenyl-2-acyl-sn-glycero-3-phosphoethanolamine (ethanolamine plasmalogen),1,2-diacyl-sn-glycero-3-phosphoethanolamine and 1-O-alkyl-2-acyl-sn-glycero-3-phosphoethanolamine, 1-O-alkenyl-2-acyl-sn-glycero-3-phosphocholine (choline plasmalogen), 1,2-diacyl-sn-glycero-3-phosphocholine and 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine, 1,2-diacyl-sn-glycero-3-phosphoinositiol (PtdIns), 1,2-diacyl-sn-glycero-3-phosphoserine (PtdSer), and sphingomyelin (CerPCho) were scraped from the plate and used to quantify either esterified fatty acid content or phospholipid content . Neutral lipids were isolated using a solvent system of heptane/isopropyl ether/glacial acetic acid (60 : 40 : 4 by vol.) on 20 9 20 cm silica gel 60 plates. Bands corresponding to cholesterol and cholesteryl esters were scraped from the plates and used to quantify content (Breackenridge and Kuksis 1968) . Gangliosides were isolated on 20 9 20 cm silica gel 60 plates using a solvent system of chloroform/methanol/water (55 : 45 : 10 by vol.). Bands corresponding to standards were visualized with a resorcinol-HCl reagent following a heating step where plates were covered with a 20 9 20 cm glass plate then heated to 105°C for 30 min (Svennerholm 1957; Ueno et al. 1978) . Fig. 1 Behavioral analysis of mice subjected to experimental autoimmune encephalomyelitis (EAE) and treated with either water (H 2 O) or glyceryl triacetate (GTA) (4 g/kg). (a) The averaged effect treatment had on daily clinical scores, (b) the averaged effect treatment had on hanging wire test, and (c) the averaged changes in body weight measured throughout the treatment period. Clinical score criteria described in (a) represents: 0, no paralysis; 1, flaccid tail; 2, mild hind limb weakness; 3, severe hind limb weakness; 4, hind limb paralysis; and 5, hind limb and forelimb paralysis. All values report the means AE SD and the asterisks represents a statistical difference (p ≤ 0.05) comparing water-treated to glyceryl triacetate-treated EAE mice (n = 24).
Quantifying phospholipid content
The individual phospholipid bands visualized with iodine vapor were quantified using a colorimetric lipid phosphorus assay (Rouser et al. 1969) . Sample and standard absorbance was measure on a DU 530 UV/VIS spectrophotometer (Beckman Coulter, Brea, CA, USA) at 797 nm. Sample concentration was assigned based on an external standard curve (3.125-400 nmol) and reported as the means AE SD in units of lmol/g wet weight and repeated in duplicate.
Quantifying ganglioside content
Individual ganglioside bands were scrapped from the TLC plates and transferred to screw top test tubes. Ganglioside content was quantified based on a resorcinol assay as described previously (Svennerholm 1957) . Absorbance was measured on a DU 530 UV/ VIS spectrophotometer (Beckman/Coulter) at 450 nm. Sample concentration was established based on an external standard curve of fructose ranging in concentration from 14 to 1800 nmol. Results are reported as the means AE SD in units of lmol/g wet weight.
Quantifying esterified fatty acid content Esterified fatty acid content from individual phospholipid bands were visualized using 6-p-toluidino naphthalene sulfonic acid (62.6 mg in 200 mL 50 mM Tris, pH 7.4) under UV light. Bands were transferred into screw top test tubes then methylated using 2% sulfuric acid in toluene/methanol (1 : 1 by vol.) for 120 min at 65°C using triheptadecanoin as an internal standard . Fatty acids were extracted in n-hexane and quantified on a gas liquid chromatograph (Shimadzu, Nakagyo-ku, Kyoto, Japan) equipped with a flame ionization detector and a SP-2330 capillary column (Supelco, Bellefonte, PA, USA). Peak area analysis of individual fatty acids was used to quantify fatty acid concentration using Simadzu EZStart software (build 14, version 7.2.1 SP1, Kyoto, Japan). Values are reported as the means AE SD in units of lmol/g wet weight and repeated in duplicate.
Quantifying cholesterol and cholesterol ester content Individual cholesterol and cholesteryl ester bands visualized using iodine vapor were transferred to screw top test tubs. Cholesterol content was quantified using an iron binding colorimetric assay (Bowman and Wolf 1962) . Absorbance was measured on a DU 530 UV/VIS spectrophotometer (Beckman/Coulter) at 550 nm, and content was calculated based on an external standard curve (582-2.27 lg). Values are reported as the means AE SD in units of lmol/g wet weight and repeated in triplicate.
Protein isolation
Frozen spinal cord samples of control mice (n = 8), EAE mice treated with water (n = 5), and EAE mice treated with GTA (n = 8) were transferred into small plastic vials containing ice-cold 50 mM Tris buffer pH = 8.0 containing 150 mM sodium chloride, 1.0% Triton X-100, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate with protease inhibitors (complete EDTA-free; Roche, Mannheim, Germany). The samples were homogenized using a polytron, allowed to incubate for 2 h at 4°C then centrifuged at 12 500 g for 20 min at 4°C. The supernatant was collected, divided into equal aliquots, and then stored at À80°C until use.
Total protein determination
Protein concentration was determined based on a micro-Bradford assay (Bradford 1976) . The absorbance was measured using Labsystem Multiskan Plus plate reader from Fisher Scientific (Waltham, MA, USA) at 595 nm, and protein concentration was determined based on an external standard curve (0.375-6 lg, bovine serum albumin).
Western blot analysis
Phospholipase and b-actin levels were measured using western blot analysis (Soliman and Rosenberger 2011; Soliman et al. 2012a Soliman et al. ,b, 2013a . Samples were separated on 7.5 or 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels using 25 lg of protein suspended in 69 loading buffer (10% 2-mercptoenthanol, 250 mM Tris at pH6.3, 60% glycerol, 6% sodium dodecyl sulfate, and 0.02% bromophenol blue) at 100 V for 2 h then transferred to nitrocellulose membranes at 100 V for 1.5 h on ice. A solution of 5% defatted milk (MP Biomedicals, Solon, OH, USA) in TTBS (Tween Tris Base Solution, 20mM Tris, 150mM NaCl, 0.05% Tween-20, pH 7.5) was used to block the membrane and during the incubation of primary antibodies targeting phospholipase C (PLC) b1, PLC d1, and b-actin (overnight at 4°C). Antibodies targeting cPLA 2 and pcPLA 2 membranes were incubated in 5% bovine serum albumin in TTBS containing the primary antibody (overnight at 4°C). The primary antibodies used were pcPLA 2 (Cell Signaling 2832, rabbit IgG, 1 : 1000), cPLA 2 (Cell Signaling 2831, rabbit IgG, 1 : 1000), PLC b1 (sc9050, rabbit IgG, 1 : 500), PLC d1 (sc30062, rabbit IgG, 1 : 1000), and b-actin (A2228, mouse IgG 2a , 1 : 2000). Membranes were washed with TTBS and then incubated with the secondary antibody for 2 h at 21-22°C: phospholipases (goat anti-rabbit IgG horseradish peroxidase, HRP, sc2004, 1 : 10 000) and b-actin (goat anti-mouse IgG 2a HRP, sc2061, 1 : 20 000). Chemiluminescent protein bands were visualized with a femto substrate (Thermo) using an Omega Lum G gel imaging station (Aplegen, San Francisco, CA, USA), and protein bands were quantified using UltraQuant software (Aplegen, Version 14.05.15). The band intensity of all phospholipase and b-actin protein bands was normalized to a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) loading control and reported as the mean AE SD (GAPDH: primary sc25778, rabbit IgG, 1 : 500; secondary sc2004, goat anti-rabbit IgG HRP, 1 : 10 000) (Markoullis et al. 2012; Schiffmann et al. 2012; Liu et al. 2015) . All western blot analyses were repeated in triplicate.
Statistical analysis
A one-way ANOVA with a Tukey-Kramer multiple comparison post-test was used to calculate statistical differences (p ≤ 0.05) between the mean AE SD values of multiple groups. Student's t test was used to quantify statistical difference between the mean AE SD values of intraday behavioral testing group. All statistical analysis was performed using GraphPad InStat software (Ver. 3.0 for Windows, San Diego CA, USA) with statistical significance set at p ≤ 0.05. To determine sample size for the experiments used in this study, we used GraphPad StatMate software (Ver. 2.0 for Windows, La Jolla, CA, USA).
Results
Acetate supplementation attenuates clinical symptoms in mice subjected to EAE Prior to and during the 40-day treatment period each mouse was assigned a daily clinical score based on the level of paralysis displayed (Kalyvas and David 2004) and weighed ( Fig. 1 ). Mice were also subjected to a hanging wire test during the treatment period to test motor strength, coordination, and grip strength (Fig. 1b) . We found that controltreated EAE mice began to develop tail paralysis on day 13 post-inoculation, experienced ascending paralysis that peaked on day 26, and remained consistent through the end of the treatment period, having an average clinical score of 3.5 (severe hind limb weakness to hind limb paralysis) (Fig. 1a) . Several of the glyceryl triacetate-treated EAE mice demonstrated tail paralysis on day 15; however, as a group none progressed beyond this stage of injury. Of the glyceryl triacetate-treated EAE mice that demonstrated tail paralysis, only one failed to regain full movement by the end of the treatment period. On day 20 through the end of the treatment period, glyceryl triacetate-treated EAE mice showed significantly less signs of injury and performed the hanging wire test significantly better than control-treated EAE mice (Fig. 1b) . On days 20 through the end of the treatment period, glyceryl triacetate-treated EAE mice were able to support their body weight up-side down for an average of 25 s compared to 1-2 s for control-treated EAE mice. In addition, there was a significant reduction in the body weight between days 20 and 34 post-inoculation comparing controltreated mice to glyceryl triacetate-treated EAE mice (Fig. 1c) . None of the control animals demonstrated changes in clinical symptoms associated with EAE (data not shown). Therefore, these animals were not subjected to the hanging wire test and their body weights were not averaged into that data found in Fig. 1(c) . This body weight shift in EAE mice treated with water paralleled the increase in clinical score and reduction in hang-time. As a whole, these data suggests that acetate supplementation prevented the onset of clinical symptoms in mice subjected to EAE.
EAE results in a reduction of spinal cord phospholipid that was not found in EAE mice treated with glyceryl triacetate To begin to determine the impact treatment had on spinal cord lipid, we quantified phospholipid content in whole spinal cords from control and EAE mice treated with either water or glyceryl triacetate. Table 1 shows the spinal cord phospholipid levels (lmol/g wet weight) of the primary phospholipid groups: ethanolamine glycerophospholipid (EtnGpl), PtdIns, PtdSer, choline glycerophospholipid (ChoGpl), and CerPCho. Mice subjected to EAE and given a control treatment showed a 30% reduction in the levels of EtnGpl, ChoGpl, and CerPCho compared to control mice treated with water or glyceryl triacetate. Furthermore, EAE resulted in a 24% reduction in PtdSer compared to control mice given glyceryl triacetate (Table 1A) . More importantly, the phospholipid levels in mice subjected to EAE and treated with glyceryl triacetate did not differ compared to either group of control mice. The levels of EtnGpl, PtdSer, and ChoGpl in the EAE-glyceryl triacetate group were significantly higher compared to mice subjected to GTA, glyceryl triacetate; EAE, experimental autoimmune encephalomyelitis; EtnGpl, ethanolamine glycerophospholipid; PtdEtn + PakEtn, 1,2-diacyl-sn-glycero-3-phosphoethanolamine and 1-O-alkyl-2-acyl-sn-glycero-3-phosphoethanolamine; PlsEtn, 1-O-alkenyl-2-acyl-sn-glycero-3-phosphoethanolamine; PtdIns, phosphatidylinositol; PtdSer, phosphatidylserine; ChoGpl, choline glycerophospholipid; PtdCho + PakCho, 1,2-diacyl-snglycero-3-phosphocholine and 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine; PlsCho, 1-O-alkenyl-2-acyl-sn-glycero-3-phosphocholine; CerPCho, sphingomyelin.
Values represent the means AE SD in units of lmol/g wet weight. The letters indicate statistical significance where 'a' represent comparisons made to water-treated control mice, 'b' represents comparison made to glyceryl triacetate-treated control mice, and 'c' represents comparison made to water-treated EAE mice.
EAE and treated with water (Table 1A) . When analysis was performed to isolate the plasmalogen fractions from ethanolamine and choline glycerophospholipid, treatment significantly increased the levels of 1,2-diacyl-sn-glycero-3-phosphoethanolamine and 1-O-alkyl-2-acyl-sn-glycero-3-phosphoethanolamine compared to all groups and returned 1,2-diacyl-sn-glycero-3-phosphocholine and 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine fraction to normal levels (Table 1B) . Treatment did not result in the recovery of the plasmalogen ethanolamine and plasmalogen choline fractions. These data suggest that increasing central nervous system acetyl-CoA metabolism may either prevent or reverse the loss of spinal cord phospholipid in mice subjected to EAE.
Acetate supplementation modulates spinal cord fatty acid content in mice subjected to EAE To determine if increasing acetyl-CoA metabolism altered fatty acid metabolism, we measured esterified fatty acid content in control and EAE mice treated with either water or glyceryl triacetate. Similar to that found in vitro , acetate supplementation did not alter the esterified phospholipid fatty acid content in control mice (Tables 2 and 3 ). However, EAE resulted in a significant reduction in the content of palmitic (16:0), stearic (18:0), oleic (18:1n-9 + n-7), arachidonic (20:4n-6), and docosatetraenoic (22:4n-6) acids in the EtnGpl and ChoGpl fractions (Table 2) . Treatment with glyceryl triacetate, however, prevented the decrease in these fatty acids returning their levels to that found in control mice. Interestingly, in mice subjected to EAE, esterified fatty acid content in PtdSer demonstrated only reductions in palmitic (16:0) and arachidonic (20:4n-6) acids with a significant increase in docosatetraenoic (22:4n-6) acid (Table 3) . Moreover, treatment with glyceryl triacetate resulted in a significant 15% increase in all fatty acid reported with the exception of palmitic acid which remained significantly decreased compared to control mice. With regard to CerPCho, EAE resulted in the significant reduction in stearic (18:0), lignoceric (24:0), and nervonic (24:1n-9) acids compared to control-treated mice. The content of these fatty acids remained significantly lower in EAE mice treated with glyceryl triacetate (Table 3) , suggesting that increasing acetyl-CoA metabolism did not alter the incorporation or turnover of N-acyl derived fatty acids associated with ceramide synthesis. Overall, these data suggest that EAE resulted in a significant decrease in lipid and fatty acid content which parallels injury severity. Treatment with glyceryl triacetate, however, returned the esterified fatty acid content in EtnGpl and ChoGpl to control levels, significantly increased content of fatty acids in PtdSer, but had no effect on fatty acid found in CerPCho. All of which suggests that increasing acetyl-CoA metabolism in mice subjected to EAE may result in an increase in acetylCoA being utilized for the synthesis of esterified fatty acid that may possibly offset that lost to injury.
Acetate supplementation prevents the loss of cholesterol in EAE mice but does not alter the EAE-induced decrease in cholesteryl esters
Similar to that found with measuring spinal cord phospholipid content, EAE significantly decreased the content of cholesterol ( Fig. 2A ) and cholesteryl esters (Fig. 2B ) compared to control mice treated with either water or glyceryl triacetate. Treatment with glyceryl triacetate significantly increased the content of cholesterol in mice subjected to EAE compared to EAE mice treated with water, but was not significantly different to that found in the control animals. On the other hand, both groups of mice subjected to EAE and treated with either water or glyceryl triacetate demonstrated a significant reduction in cholesteryl ester levels compared to control mice treated with either water or glyceryl triacetate. These data suggest that, similar to the esterified fatty acid content studies, increasing acetyl-CoA metabolism may act to restore spinal cord cholesterol content to control levels but had no effect on cholesteryl ester content.
Acetate supplementation alters GD3 and GD1a spinal cord ganglioside content but not GM1 Figure 3 shows ganglioside content in control and EAE mice treated with either water or glyceryl triacetate. GD3 content was significantly decreased in response to EAE when compared to control mice (Fig. 3A) . Acetate supplementation on the other hand resulting in a significant increase in GD3 content when compared to control mice treated with glyceryl triacetate and EAE mice treated with water. Furthermore, GD1a content was significantly decreased in animals subjected to EAE when compared to control animals ( Fig. 3B) . Acetate supplementation significantly increased GD1a levels compared to mice subjected to EAE and treated with water, but this increase was significantly less than that found in control animals. GM1 levels were significantly decreased in both EAE mice and EAE mice treated with glyceryl triacetate compared to controls (Fig. 3C) . In addition, there were significant decreases in GT1a, GD2, GD1b, and GQ1b levels in mice subjected to EAE that remained decreased with treatment (Fig. 3D ).
Acetate supplementation returns cytosolic phospholipase A 2 (cPLA 2 ) to baseline, but EAE and treatment did not alter PLC levels In peripheral nerve cell cultures, an alteration in actin polymerization is associated with myelin fragmentation (Jung et al. 2011) and is increased in Lewis rats subjected to EAE during the chronic injury phase (Smerjac and Bizzozero 2008) . To determine the impact injury and treatment had on b-actin in the mouse, we measured its levels in control and EAE mice treated with either water or glyceryl triacetate. We found that mice subjected to EAE and treated with water resulted in a significant twofold increase in b-actin levels when normalized to GAPDH (Fig. 4F) , consistent with the demyelinating injury. In EAE animals treated with glyceryl triacetate, we found a slight decrease in b-actin levels that were not significantly different from control or EAE mice treated with water. These data, as expected, suggest the EAE in the mouse increases b-actin levels (Smerjac and Bizzozero 2008; Jung et al. 2011) . However, the decrease in b-actin in the glyceryl triacetatetreated EAE mice suggests that treatment may not completely reverse all aspects of injury associated with EAE despite the clear reduction in the onset of clinical signs in this model. bactin alone is not a direct measure of neuronal injury, and future experiments will understand changes in other structural proteins like Cofilin 1 (Tilve et al. 2015) in this model. Figure 4 (A-E) shows spinal cord phospholipase protein levels in control mice and mice subjected to EAE that were treated with either water or glyceryl triacetate. These data show that in control-treated EAE mice, there was a significant increase in phosphorylated (pcPLA 2 ) and nonphosphorylated cPLA 2 when normalized to GAPDH ( Fig. 4A and B) . Similar to that found in cell culture (Soliman et al. 2013b) , acetate supplementation prevented the increase in spinal cord cPLA 2 resulting in levels similar to that found in control animals. In addition, the ratio of pcPLA 2 to total cPLA 2 did not change between the three groups analyzed suggesting that at 40 days post-inoculation the phosphorylation state of cPLA 2 was not increased (Fig. 4C) . Because the ratio of pcPLA 2 /cPLA 2 was not changed in those samples measured, the physiological Fig. 2 Cholesterol and cholesteryl ester content in control mice (n = 6) and experimental autoimmune encephalomyelitis (EAE) mice (n = 8) treated with either water (H 2 O) or glyceryl triacetate (GTA) (4 g/kg).
The spinal cord content of (A) cholesterol and (B) cholesteryl ester. Sample sizes were n = 6 for control groups and n = 8 for EAE groups. Significant differences (p ≤ 0.05) are indicated with a letter where 'a' represents comparisons made to the control mice treated with water, 'b' represents comparison to the control mice treated with glyceryl triacetate, and 'c' represents comparison made to the EAE mice treated with water. Fig. 3 Ganglioside content in control (n = 6) and experimental autoimmune encephalomyelitis (EAE) mice (n = 8) treated with either water (H 2 O) or glyceryl triacetate (GTA) (4 g/kg). The spinal cord content of (A) GD3, (B) GD1a, (C) GM1, and (D) GT1a, GD2, GD1b, and GQ1b. Samples sizes were n = 6 for control groups and n = 8 for EAE groups. Significant differences (p ≤ 0.05) are indicated with a letter where 'a' represents comparison made to control mice treated with water, 'b' represents comparison made to control mice treated with glyceryl triacetate, and 'c' represents comparison made to EAE mice treated with water.
significance regarding total PLA 2 enzymatic activity and cellular localization within the spinal cord remains to be determined and is a subject for future studies. Furthermore, neither EAE nor treatment altered spinal cord protein levels of PLC b and PLC d when normalized to GAPDH as shown in Fig. 4(D) and (E), respectively. These results suggest, similar to that reported previously (Kalyvas and David 2004) , that cPLA 2 may play a greater role in EAE-mediated demyelination compared to PLC and that acetate supplementation with glyceryl triacetate may attenuate PLA 2 -mediated lipid signaling.
Acetate supplementation prevented the loss of myelin staining A histochemical analysis was performed using FluoroMyelin TM green to visualize changes in myelin content from lumbar regions of the spinal cord in control, EAE, and EAE mice treated with glyceryl triacetate. Low magnification (409) results show very distinct FluoroMyelin TM staining along the outer edges of the spinal cord in the spinocerebellar and fasciculus regions that was decreased in intensity in samples taken from mice subjected to EAE (Fig. 5a-c) . High magnification (4009) analysis of control samples show that fluorescent staining is confined within a tight band along the outer surface on the spinal cord (ventral spinocerebellar track) with distinct vertical striations (Fig. 5d) . The intensity of fluorescent staining was reduced in animals subjected to EAE in this region having a diffuse outer band with no apparent vertical striations (Fig. 5e) . EAE animals treated with glyceryl triacetate demonstrated fluorescent intensity similar to that found in control animals having an outer band with some vertical striations (Fig. 5f ). average length measured of the spinocerebellar and fasciculus region of control, EAE mice, and EAE mice treated with GTA. These data show a decrease in the length comparing control to EAE mice that was recovered slightly with GTA treatment. These data suggest that glyceryl triacetate may be positively influencing myelin content in mice subjected to EAE, but at a degree lower than that found in control animals.
Discussion
In this study, we found that acetate supplementation attenuated clinical signs and prevented the loss of many spinal cord lipid components in mice subjected to EAE. Furthermore, acetate supplementation returned cPLA 2 and pcPLA 2 to control levels, which suggests that glyceryl triacetate may alter lipid deposition and/or breakdown in this model and potentially disrupt PLA 2 -mediated lipid signaling. In addition, treatment maintained myelin lipid content and some structural characteristics with the spinal cord based on FluoroMyelin TM staining. These results support the hypothesis that increasing brain acetyl-CoA metabolism in mice subjected to EAE can alter adult spinal cord lipid metabolism which may potentially offset that lost to injury.
In this regard, de novo fatty acid synthesis is initiated by the conversion of acetyl-CoA to malonyl-CoA by the enzyme acetyl-CoA carboxylase. Monounsaturated fatty acids can be synthesized from the newly formed and dietary saturated fatty acids via the action of delta-9-desaturase enzymes forming both oleic and palmitoleic acids (Jaworski et al. 2016) . Therefore, having a reservoir of fatty acid based on diet, turnover, and de novo synthesis is essential to maintain phospholipid homeostasis as each phospholipid moiety contains on average two fatty acids esterified at the sn-1 and sn-2 positions of its glyceryl backbone (Baenke et al. 2013) . Central nervous system acetyl-CoA can also be utilized in the formation of cholesterol via the formation of 3-hydroxy-3-methylglutaryl-CoA, the rate-limiting step in cholesterol synthesis (Jaworski et al. 2016) . These pathways are active during myelin development and during periods of rapid lipid turnover found with injury (Moser et al. 1999; Rosenberger et al. 2002 Rosenberger et al. , 2004 Ando et al. 2003) .
During injury, there is a rapid increase in the turnover of lipid resulting from an increase in expression and activity of enzymes that metabolize lipid. For example, in rats, the metabolism of arachidonic acid is significantly increased with an increase in phospholipase A 2 -catalyzed arachidonic acid turnover and prostaglandin production (Murphy et al. 2000; Rosenberger et al. 2004) . Cytosolic PLA 2 pathway is highly expressed during injury and chronic inflammation in the central nervous system, which may contribute to the loss of myelin and myelin phospholipid (Farooqui et al. 1997; Rosenberger et al. 2002; Kalyvas and David 2004) . Thus, to prevent injury there will be a need to increase the rate of lipid synthesis to replenish that content lost. Central nervous system lipid content is maintained based primarily on the incorporation of dietary lipid. Acetate, however, can be utilized for de novo synthesis of lipid within the central nervous system provided the necessary metabolic and enzymatic machinery are in place (D'Adamo and Yatsu 1966) . With regard to control animals given acetate supplementation and in control glial cell cultures, acetate is utilized to increase phosphocreatine levels but does not alter 3-hydroxy-3-methylglutaryl-coenzyme A, fatty acid, phospholipid, or cholesterol levels (Bhatt et al. 2013) . In LPSstimulated microglia on the other hand, acetate significantly increases fatty acid content suggesting that increases in metabolic demand because of the pro-inflammatory endotoxin induces compensatory pathways favoring an increase in the incorporation and synthesis of lipid. Furthermore, LPS increases phospholipase and cyclooxygenase levels in microglia and astrocytes that are attenuated by acetate (Soliman et al. 2013b) , which further suggest acetate supplementation may positively influence an increase in the rate of lipid deposition in the central nervous system. Because acetate supplementation can increase both histone and non-histone protein acetylation suggests that altering the acetylated protein within the cell may alter how the cell responds to LPS-induced inflammatory signaling. One particular pathway activated following a pro-inflammatory stimulus is the NF-jB pathway. However, when p65 subunit is acetylated, this pathway is inhibited (Kiernan et al. 2003) . This supports the idea that protein acetylation can promote a shift from a pro-inflammatory to an anti-inflammatory state, which in turn may promote a normalization in the turnover of lipid. In a control state, the metabolic demand, and in turn, the turnover of lipid, is substantially less than that found within a pro-inflammatory state (Rosenberger et al. 2004) . However, following an inflammatory stimulus, substantially increasing acetyl-CoA content may increase the acetylation of p65, down-regulate NF-jB signaling pathways, and reduce the overall inflammatory state (Soliman et al. 2012a (Soliman et al. , 2013a . Since, as we know, acetate supplementation increases histone acetylation in neuroglia and neuroinflammation models (Soliman and Rosenberger 2011; Soliman et al. 2012a Soliman et al. ,b, 2013a , this implies that treatment may promote a decrease in the expression of pro-inflammatory enzymes and potentially an increase in the expression of enzymes involved in lipid synthesis to promote deposition of lipid. Therefore, during injury, changes in histone and protein acetylation in the presence of high concentration of acetate and acetyl-CoA may result in a metabolic shift resulting in an increase in lipid synthesis, a normalization of pro-inflammatory signaling, and reduction in PLA 2 -mediated lipid breakdown.
Several metabolic disorders are characterized by defects in lipid synthesis resulting in changes in lipid composition suggesting that an offset in the balance between lipid deposition and breakdown may result in the loss of function. In particular, Sjogren-Larsson, Resfum disease, NiemannPick disease show an increase in long-chain fatty alcohol levels, dysfunction in a-oxidation, or glycosphingolipid accumulation, which disrupts myelin stability, assembly, and compactness (Chrast et al. 2011) , that in turn alters axonal function, axon-glia interactions, and disrupts lipidmediated signaling (Chrast et al. 2011; Schmitt et al. 2015) . In addition, Smith-Lemli-Opitz syndrome displays a dysfunction in the cholesterol metabolism because of a mutation in the enzyme involved in the final step of cholesterol synthesis. This results in an increase in cholesterol metabolites, but an overall decrease in cholesterol (Chrast et al. 2011) . In this disease, it is suggested that the inability to incorporate cholesterol into myelin membrane results in the loss of myelin. Interestingly, treatment involving cholesterol supplementation in combination with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors shows an increase in plasma cholesterol and a decrease in its metabolites (Haas et al. 2007; Chan et al. 2009 ). This suggests a potential change in the rate of lipid deposition by supplying the system with dietary cholesterol. Furthermore, lovastatin, a brain penetrate HMG-CoA reductase inhibitor, significantly increases myelin lipid levels and augment the survival and differentiation of oligodendrocyte progenitor cells in the Lewis rat subjected to EAE (Paintlia et al. 2005) . All of which support the premise that a primary change in the rate of lipid deposition can result in injury within the central nervous system.
In this regard, changes in central nervous system lipid metabolism may also to contribute to demyelinating diseases associated with other metabolic disorders. For example, in Canavan disease there is an accumulation of N-acetyl aspartate in the brain because of a loss in aspartoacylase activity. The functional loss of aspartoacylase promotes a decrease in the utilization of N-acetyl aspartate and the production of acetate used for lipid synthesis which contributes to demyelination (Mathew et al. 2005; Madhavarao et al. 2009; Arun et al. 2010b; Segel et al. 2011) . Currently, no treatment or cure is available for patients with this disease. However, it is known that acetate supplementation is clinically beneficial and safe in clinical and preclinical studies for Canavan disease (Madhavarao et al. 2009; Segel et al. 2011) . Infants with this disease were given a low dose of glyceryl triacetate, which was found to be tolerable and safe in these patients. However, treatment did not significantly improve or worsen clinical symptoms (Madhavarao et al. 2009) . In preliminary studies, we administered glyceryl triacetate to EAE mice after they exhibited hind limb paralysis. In these studies, acetate supplementation did not improve onset of paralysis but also did not worsen symptoms (data not shown). Comparing these preliminary results to that outlined in this manuscript suggests that there may be a therapeutic window in this model at which treatment may be effective in offsetting the loss of spinal cord lipid because of injury. Furthermore, those animals in our treatment study that experienced a reversal in tail paralysis during the treatment period support this premise. Once disease has progressed to the extent where the nascent and adult oligodendroglia remain viable, acetate supplementation may not be effective in preventing or reversing disease progression alone. Further studies are warranted regarding the effectiveness of interventional acetate treatment in reversing or slowing the loss of myelin in mice demonstrating differing stages of paralysis. Also, further studies are needed to understand the role of acetate supplementation in relapse remitting forms of multiple sclerosis potentially showing a progression of the remitting stage and/or a decrease in the relapse stage.
Therapeutic dietary fatty acid supplementation is not a new concept in the treatment of metabolic diseases. Oleic acid supplementation is effective in patients who suffer from adrenoleukodystrophy, a disease resulting in a decrease in very long-chain fatty acid (VLCFA) uptake into the peroxisome (Chrast et al. 2011) and an increase in plasma VLCFA levels (Moser et al. 1981; Chrast et al. 2011; Poll-The and Gartner 2012) . The inability of VLCFA to be transported into peroxisome results in a dysfunction in fatty acid metabolism resulting in a loss of short-chain fatty acids, a disruption in membrane dynamics, and a decrease in fatty acid oxidation (Weller et al. 2003; Steinberg et al. 2004 Steinberg et al. , 2006 Wanders and Waterham 2006; Wanders et al. 2010; Kihara 2012) . In patients with adrenoleukodystrophy, there is an increase in the production of leukotrienes within the central nervous system that promotes immune-mediated demyelination (Mayatepek et al. 1993; Mayatepek and Tiepelmann 1996) . Thus, it is important to maintain fatty acid homeostasis to maintain normal brain function (Kihara 2012) . Oleic acid is an 18 carbon monounsaturated fatty acid which inhibits the elongation of VLCFA (Moser et al. 1987; Rizzo et al. 1987) . Oleic acid supplementation given to adrenoleukodystrophy patients as glyceryl trioleate decreases plasma VLCFA, improves clinical symptoms (Moser et al. 1987) , and potentially normalizes fatty acid ratios within the central nervous system (Deon et al. 2008) . Alternative experimental therapies also include a combination of different triglycerides, glyceryl trioleate and glyceryl trierucate (4 : 1 by vol., Lorenzo's oil) that may be more clinically beneficial in lowering VLCFA. In fact, Lorenzo's oil lowers plasma VLCFA, increases peroxisomal function (Moser et al. 1999 (Moser et al. , 2007 Deon et al. 2008) , and improves peroxisomal fatty acid oxidation (Wanders and Waterham 2006; Wanders et al. 2010) . In addition, Lorenzo's oil treatment inhibits ELOVL 1, an enzyme involved in VLCFA synthesis (Sassa et al. 2014 ) suggesting a potential mechanism of action that may lead to an improvement in metabolic dysfunction in this disease.
Similarly, docosahexaenoic acid (DHA) is another form of dietary fatty acid supplementation that shows therapeutic promise in patients who suffer from the peroxisomal disorder, Zellweger syndrome. Zellweger syndrome results in a dysfunction in fatty acid oxidation that contributes to an accumulation of fatty acids, a decrease in plasmalogen levels, and hypomyelination (Ferdinandusse et al. 2001; Weller et al. 2003; Chrast et al. 2011; Poll-The and Gartner 2012) . Docosahexaenoic acid supplementation improves neuronal function related to vision and muscle movement in young children and infants (Martinez et al. 1993 (Martinez et al. , 2000 Martinez 1996 Martinez , 2001 , returns plasma docosahexaenoic acid and plasmalogen to normal (Martinez et al. 2000) , and improves myelination as shown in MRI scans of patients given DHA supplementation (Martinez and Vazquez 1998; Martinez et al. 2000) . Interestingly, for DHA supplementation to be effective, patients need to be treated early in development (Martinez et al. 2000; Martinez 2001) suggesting that the disruption in lipid metabolism, similar to that found in this study, must be addressed prior to the loss of cellular function to be effective.
Multiple sclerosis is characterized as an inflammatory demyelinating disease (Denic et al. 2011; Lassmann and van Horssen 2011; Cusick et al. 2013) ; however, it is not clear if the disease also maintains an underlying metabolic dysfunction in lipid metabolism. If this is the case, then current available therapies that treat only a portion of the disease by targeting peripheral immune cell infiltration and pro-inflammatory signaling (Lim and Constantinescu 2010; Minagar 2013) may not be effective at inhibiting the onset of symptoms. Because it is known that MS also results in an increase in phospholipase A 2 activity and expression supports the idea that the disease may also be the result of a metabolic dysfunction in lipid metabolism. In the EAE model, there is a significant increase in cPLA 2 levels that contribute to an increase in proinflammatory eicosanoid signaling, which parallels the immune cell infiltration into the central nervous system and demyelination (Kalyvas and David 2004; Braverman and Moser 2012) . In our study, the EAE resulted in a significant increase in cPLA 2 levels consistent with previous studies (Kalyvas and David 2004) . We found that acetate supplementation returned levels back to baseline potentially exhibiting an anti-inflammatory effect. This may be a result in a metabolic shift induced by changes in histone and non-histone protein acetylation (Reisenauer et al. 2011; Soliman and Rosenberger 2011; Soliman et al. 2012a Soliman et al. ,b, 2013a . In LPS-stimulated neuroglia, acetate alters the expression of phospholipases and cyclooxygenase enzymes that correlate to a change in histone acetylation (Soliman et al. 2013b ) of which suggests that posttranslational acetylation can influence lipid breakdown and deposition.
The hypothesis that MS may also be a metabolic disorder may help explain the overall decrease in lipid content, which may be a result of a decrease in the rate of lipid synthesis. It is well known that phospholipid, cholesterol, plasmalogen, and cerebroside levels are decreased in patients who suffer from multiple sclerosis (Cumings 1953 (Cumings , 1969 Gerstl et al. 1961 Gerstl et al. , 1970 . Specifically, in white matter, there is a decrease in PtdSer, PtdIns, EtnGpl, and CerPCho in EAE mice (Salvati et al. 1990 ). The question remains whether this loss in lipid content is a result of a metabolic dysfunction or the result of immune-targeted degradation of myelin membranes. In this study, we showed that acetate supplementation prevented the loss of EtnGpl, ChoGpl, and PtdSer but did not affect spinal cord levels of PtdIns and CerPCho. It is known that in animals subjected to EAE, injury results in a significant increase in cholesteryl ester content during active demyelination (Roth et al. 1982; Taranova 1985) . However, we found a decrease in cholesteryl ester content in our samples collected on average 20 days post-active demyelination. Suggesting that difference between the cholesteryl esters may be a result of the active-and post-demyelinating stage of injury. In this study, we included control mice who did not receive adjuvant or pertussis toxin injections unlike those mice subjected to EAE. Similar to that reported in vitro, we found that glyceryl triacetate alone did not change lipid levels in controls supporting the premise that an injury stimulus is needed to increase the metabolic demand for lipid production . There are, however, limitations in using control mice over sham mice. Adjuvant or pertussis toxin may introduce complicating effects because of the transient peripheral inflammatory reaction to these compounds. However, there is no information to suggest that vehicle will result in significant or sustained changes in lipid metabolism or content within the spinal cord (Salvati et al. 1990; Revina et al. 2001) . Nonetheless, EAE injury resulted in a loss of spinal cord lipid that was recovered, at least in part, with glyceryl triacetate treatment. If acetate supplementation is primarily an anti-inflammatory agent, one would expect that treatment would slow or reverse the degradation of all spinal cord lipids. Because treatment did not restore all lipid components to control levels, this implies that treatment may alter the expression of enzymes involved in specific lipid synthesis pathways promoting lipid deposition or decreasing lipase expression and breakdown.
In this regard, GD1a within the central nervous system is a ligand for myelin-associated glycoprotein (MAG) whose interactions promote myelin stability and inhibit nerve regeneration by reducing nerve sprouting (Schnaar 2010; Schmitt et al. 2015) . Both of which are important in maintaining normal function within the central nervous system (McKerracher et al. 1994; Mukhopadhyay et al. 1994; Yang et al. 1996; Chiavegatto et al. 2000; Schachner and Bartsch 2000; Vyas and Schnaar 2001; Vyas et al. 2002; Pan et al. 2005; Schnaar et al. 2014) . GD1a was significantly elevated in EAE mice treated with glyceryl triacetate, but levels did not completely return to control. Suggesting a reduction in the interaction of GD1a and MAG possibly because of an increase in the inflammatory response that may limit GD1a/MAG interactions with an anti-ganglioside antibody attack to ganglioside content altering myelin stability (Acarin et al. 1996; Sadatipour et al. 1998; Mata et al. 1999) . Histochemical analysis of spinal cord samples using FluoroMyelin TM suggests distinct structural differences in myelin when comparing control mice to those subjected to EAE that was recovered impart with glyceryl triacetate. In addition, acetate supplementation significantly increased GD3 levels in EAE mice compared to EAE mice treated with water and control animals treated with glyceryl triacetate. Thus, the dramatic loss of lipid because of the EAE may result in the metabolic need to increase GD3 content compared to GM1 similar to a developing brain (Rosner et al. 1985; Kracun et al. 1991) . Because FluoroMyelin TM binds to myelin via lipophilic affiliation suggests that treatment may increase phospholipid content in those myelinated regions, while changes in ganglioside content as a result of EAE may provide insight into the structural changes observed. Therefore, further study is needed to understand how treatment alters specific pathways in the metabolism of spinal cord lipid and to further understand how this might prevent the loss of myelin membrane and myelin function.
In conclusion, acetate supplementation prevented the onset of clinical signs of paralysis and prevented the loss of many lipid components found in the spinal cord. These data suggest that EAE-induced paralysis may be the result of both an immune-mediated attack on myelin and possibly a disruption in the metabolism of spinal cord lipid. In this regard, there are many metabolic disorders that exhibit a dysfunction in lipid metabolism that can contribute to alterations in myelin lipid content. Therefore, understanding how EAE disrupts lipid metabolism may provide insight into the impact metabolism has on the induction and progression of injury associated with multiple sclerosis. It will be of interest to expand these studies to fully investigate the mechanism(s) by which an increase in the metabolism of central nervous system acetyl-CoA reduces pro-inflammatory signaling and potentially alters the metabolism of lipid. These may provide a basis to develop therapeutics focused toward increasing the rate of lipid deposition to offset that lost to injury.
